Vanda's second Phase 3 test of milsaperidone in depression targets Q1 2027
Already approved for bipolar I and schizophrenia, milsaperidone now faces a randomized, placebo-controlled trial testing whether it works as an add-on antidepressant in a crowded MDD field.
Executive Summary
- Vanda Pharmaceuticals is running a randomized, placebo-controlled Phase 3 trial testing an already-approved antipsychotic as an add-on antidepressant, a use distinct from the indications for which the drug currently carries FDA approval.
- The sponsor has guided to a Q1 2027 topline readout even though the trial's own registry completion date sits more than a year later, a gap that puts the near-term guidance ahead of the study's stated operational timeline.
- Enrollment and protocol activity show no disruption since the study opened, so execution is not the open question here; the question is what the MADRS-based endpoint shows once analyzed.
- The depression field carries a wide range of active late-stage programs testing different mechanisms, so a positive result would add a differentiated option to that field rather than validate or invalidate a contested mechanism shared by rivals.
The trial
The Phase 3 study, registered as NCT06830044, randomizes adults aged 18 to 65 with major depressive disorder who show an inadequate response to antidepressant therapy, confirmed using the Antidepressant Treatment Response Questionnaire. Patients are assigned to milsaperidone or placebo in a two-arm design, with the primary endpoint measuring change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician-rated 10-item scale of depression symptom severity. The trial targets 500 patients across sites in the United States, Czechia, Poland, and Bulgaria, and has been recruiting since May 27, 2025, after opening as not-yet-recruiting three months earlier. NCT06830044Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the drug already has
Milsaperidone, marketed as BYSANTI, received FDA approval for bipolar I disorder and schizophrenia on February 20, 2026, giving Vanda a commercial base to build on and data exclusivity through February 2031. That approval means the MDD study is not a first-in-human or first-registrational test of the molecule; it is an effort to extend an approved drug's label into a new adjunctive-depression use, a bar that rests on replicating an antidepressant effect against placebo rather than establishing basic safety and tolerability for the first time. VandaVanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 6, 2026
Timing signal
Vanda's first-quarter 2026 disclosure guided this trial's topline results to the first quarter of 2027, a narrower window than the same trial carried in prior disclosures, which had pointed to results sometime in 2026. That guided window sits well ahead of the trial's own registry primary completion date of March 1, 2028, a date that has not moved since the study was first submitted. The registry shows no amendments to the primary endpoint, no change in enrollment target, and only a single eligibility-criteria update since the study opened, consistent with a protocol that has been stable through its first year and a half of recruiting. Vanda+1Vanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 6, 2026Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044
The competitive field
No trial in the current major depressive disorder landscape shares milsaperidone's mechanism, and the nearest comparators, including Takeda's vortioxetine, Janssen's esketamine and seltorexant, Neurocrine's NBI-1065845, Axsome's solriamfetol, and Cybin's CYB003, work through different mechanistic pathways in the same indication. That leaves milsaperidone without a same-mechanism precedent to benchmark its adjunctive-MDD effect against, so the trial's own data will be the first test of whether this specific drug's profile extends from bipolar I disorder and schizophrenia into depression augmentation.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.